Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company’s laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
BörsenkürzelFLGT
Name des UnternehmensFulgent Genetics Inc
IPO-datumSep 28, 2016
CEOMr. Ming Hsieh
Anzahl der mitarbeiter1313
WertpapierartOrdinary Share
GeschäftsjahresendeSep 28
Addresse4399 Santa Anita Ave
StadtEL MONTE
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl91731
Telefon16263500537
Websitehttps://www.fulgentgenetics.com/
BörsenkürzelFLGT
IPO-datumSep 28, 2016
CEOMr. Ming Hsieh
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten